Pharmaron Beijing Co., Ltd.

300759

CNE100003JW4

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2025-01-20			5-day change	1st Jan Change
25.51 ^CNY	+1.80%		+4.51%	-0.74%

Dec. 16	Pharmaron Beijing Co., Ltd. commences an Equity Buyback Plan for 15,076,856 shares, representing 0.84% of its issued share capital, under the authorization approved on June 6, 2024.	CI
Dec. 09	Pharmaron Beijing Plans Up to 50 Million Yuan Share Repurchase	MT

Yuyue Medical to Transfer Share in AstraZeneca Fund to Pharmaron

August 19, 2024 at 02:07 am EDT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd. commences an Equity Buyback Plan for 15,076,856 shares, representing 0.84% of its issued share capital, under the authorization approved on June 6, 2024.	Dec. 16	CI
Pharmaron Beijing Plans Up to 50 Million Yuan Share Repurchase	Dec. 09	MT
Pharmaron Beijing Posts 13% Fall in Q3 Profit	24-10-29	MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-29	CI
Pharmaron Beijing Posts Nearly 42% Higher Profit in H1; Stocks Up By 4%	24-08-28	MT
Nomura Adjusts Pharmaron Beijing's Price Target to 29.73 Yuan From 31.41 Yuan, Keeps at Buy	24-08-28	MT
Nomura Adjusts Pharmaron Beijing's Price Target to HK$14.31 From HK$15.41, Keeps at Buy	24-08-28	MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-27	CI
Yuyue Medical to Transfer Share in AstraZeneca Fund to Pharmaron	24-08-19	MT
Pharmaron Beijing Buys Back Over 9.6 Million A Shares	24-07-29	MT
Tranche Update on Pharmaron Beijing Co., Ltd.'s Equity Buyback Plan announced on April 25, 2024.	24-07-26	CI
Pharmaron Beijing Co., Ltd.'s Equity Buyback announced on April 25, 2024, has closed with 9,608,288 shares, representing 0.54% for CNY 200.09 million.	24-07-24	CI
Pharmaron Beijing's H1 Profit to Jump Up to 45%, Revenue to Slip Up to 3%; Shares Climb 7%	24-07-22	MT
Pharmaron Beijing Buys Back, Applies to Delist Convertible Bonds	24-07-04	MT
Tranche Update on Pharmaron Beijing Co., Ltd.'s Equity Buyback Plan announced on April 25, 2024.	24-07-02	CI
Pharmaron Beijing's Unit Receives Initial Payment for Disposal of Stake in Proteologix	24-06-25	MT
Pharmaron Beijing Redeems 1.92 Billion Yuan Convertible Bonds	24-06-20	MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	24-06-19	CI
Pharmaron Beijing Unit to Sell Proteologix Stake to Johnson & Johnson	24-05-20	MT
Johnson & Johnson entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	24-05-15	CI
Pharmaron Beijing's Profit Rises 17% in 2023	24-04-30	MT
Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy	24-04-29	MT
Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%	24-04-26	MT
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy	24-04-26	MT
Pharmaron Beijing To Repurchase Shares Worth Up To 300 Million Yuan; Shares Jump 8%	24-04-26	MT

Chart Pharmaron Beijing Co., Ltd.

Duration

Period

300759: Dynamic Chart

Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

Employees

20,295

Sector

Biotechnology & Medical Research

Calendar

2025-03-30 - Q4 2024 Earnings Release (Projected)

More about the company